NCT04223960View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

184

Participants

Timeline

Start Date

January 9, 2020

Primary Completion Date

August 6, 2023

Study Completion Date

August 6, 2023

Conditions

Healthy Volunteers

Interventions

DRUG

EA1080

EA1080 Formulation A.

DRUG

EA1080

EA1080 Formulation B.

DRUG

EA1080

EA1080 Formulation C.

DRUG

EA1080

EA1080 Formulation D.

DRUG

EA1080-matching placebo

EA1080-matching placebo.

DRUG

EA1080

EA1080 Formulation E.

DRUG

EA1080

EA1080 Formulation F.

Trial Locations (1)

Unknown

Richmond Pharmacology Ltd, London

All Listed Sponsors

lead

EA Pharma Co., Ltd.

INDUSTRY

NCT04223960 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Participants | Biotech Hunter | Biotech Hunter